Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients.
Nicholas C AllenAndrew J MartinVictoria A SnaidrRenee EgginsAlvin H ChongPablo Fernandéz-PeñasDouglas GinShireen SidhuVanessa L PaddonLeith A BanneyAdrian LimEdward UpjohnHelmut SchaiderAparna D GanhewaJennifer NguyenCatriona A McKenzieSaurabh PrakashCatriona McLeanAlistair LochheadJan IbbetsonAndrew DettrickAnthony LandgrenKatherine J AllnuttClare AllisonRachael B DavenportBlake P MumfordBrittany WongBrendan StaggAlexander James TedmanHannah GribbinHarrison A EdwardsNicholas De RosaThomas StewartBrent J DoolanYonatan KokKate SimpsonZhi M LowTom KovitwanichkanontRichard A ScolyerHaryana M DhillonJanette L VardySteven J ChadbanDavid G BowenAndrew C ChenDiona L DamianPublished in: The New England journal of medicine (2023)
In this 12-month, placebo-controlled trial, oral nicotinamide therapy did not lead to lower numbers of keratinocyte cancers or actinic keratoses in immunosuppressed solid-organ transplant recipients. (Funded by the National Health and Medical Research Council; ONTRANS Australian New Zealand Clinical Trials Registry number, ACTRN12617000599370.).